Skip to content
Triangle logo TriangleGet started
← Uterine Neoplasm

NCT00282087 · STUDY IN CONTEXT

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS

Source null

→

secondary · POSTED

Unacceptable toxicity is defined as grade 3 or 4 non-hematologic toxicity events that are considered to be treatment-related, excluding alopecia and fatigue.

Source null

→

secondary · POSTED

Correlation Between Age and Tumor Response to Treatment (PFS)

Source null

→

secondary · POSTED

Correlation Between Menopausal Status at Diagnosis and Tumor Response to Treatment (PFS)

Source null

→

secondary · POSTED

AJCC Stage I: No serosal involvement AJCC Stage II: No serosal involement AJCC Stage III: Serosal only

Source null

→

secondary · POSTED

Mitotic rate is measured in mitoses per 10 high-power fields

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-uterine-neoplasm
nct id
NCT00282087
trial label
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
6
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0000
    source section id
    NCT00282087-om-0000
    source outcome index
    0
    endpoint
    Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS
    endpoint definition
    Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS
    time origin
    Every 3 months up to two years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0001
    source section id
    NCT00282087-om-0001
    source outcome index
    1
    endpoint
    Tolerability/Toxicity of This Regimen
    endpoint definition
    Unacceptable toxicity is defined as grade 3 or 4 non-hematologic toxicity events that are considered to be treatment-related, excluding alopecia and fatigue.
    time origin
    Every 28 days during dosing and then every 3 months thereafter until patient comes off study
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0002
    source section id
    NCT00282087-om-0002
    source outcome index
    2
    endpoint
    Correlation Between Age and Tumor Response to Treatment (PFS)
    endpoint definition
    Correlation Between Age and Tumor Response to Treatment (PFS)
    time origin
    2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0003
    source section id
    NCT00282087-om-0003
    source outcome index
    3
    endpoint
    Correlation Between Menopausal Status at Diagnosis and Tumor Response to Treatment (PFS)
    endpoint definition
    Correlation Between Menopausal Status at Diagnosis and Tumor Response to Treatment (PFS)
    time origin
    2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0004
    source section id
    NCT00282087-om-0004
    source outcome index
    4
    endpoint
    Correlation Between Uterine Serosal Involvement and Tumor Response to Treatment (PFS)
    endpoint definition
    AJCC Stage I: No serosal involvement AJCC Stage II: No serosal involement AJCC Stage III: Serosal only
    time origin
    2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0005
    source section id
    NCT00282087-om-0005
    source outcome index
    5
    endpoint
    Correlation Between Mitotic Rate and Tumor Response to Treatment (PFS)
    endpoint definition
    Mitotic rate is measured in mitoses per 10 high-power fields
    time origin
    2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    regimen
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    analyzed count
    46
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00282087-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    regimen
    Number of major toxicity events
    analyzed count
    46
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00282087-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    regimen
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    analyzed count
    47
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00282087-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    regimen
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    analyzed count
    47
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00282087-om-0003#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0004
    arm key
    OG000
    arm label
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    regimen
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    analyzed count
    47
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00282087-om-0004#groups/OG000
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    outcome key
    om-0005
    arm key
    OG000
    arm label
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    regimen
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    analyzed count
    47
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00282087-om-0005#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-neoplasm
    nct id
    NCT00282087
    harm key
    EG000
    source section id
    NCT00282087-ae
    event group key
    EG000
    event group label
    Women Treated With Adjuvant Regimen for High Risk Uterine LMS
    serious affected
    9
    serious at risk
    47
    other affected
    14
    other at risk
    47
    frequency threshold
    4
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice